Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
The efficacy of tocilizumab was tested in a randomized, controlled trial involving patients with Covid-19 who had fever, pulmonary infiltrates, or a need for supplemental oxygen. The treatment had no significant effect on disease progression, independence from supplemental oxygen, or death.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine Jg. 383; H. 24; S. 2333 - 2344 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
Massachusetts Medical Society
10.12.2020
|
| Schlagworte: | |
| ISSN: | 0028-4793, 1533-4406, 1533-4406 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Zusammenfassung: | The efficacy of tocilizumab was tested in a randomized, controlled trial involving patients with Covid-19 who had fever, pulmonary infiltrates, or a need for supplemental oxygen. The treatment had no significant effect on disease progression, independence from supplemental oxygen, or death. |
|---|---|
| Bibliographie: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 A complete list of the BACC Bay Tocilizumab Trial investigators and members of the data and safety monitoring board is provided in the Supplementary Appendix, available at NEJM.org. |
| ISSN: | 0028-4793 1533-4406 1533-4406 |
| DOI: | 10.1056/NEJMoa2028836 |